RANCHO CORDOVA, Calif., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, announced today it will report financial results for the fiscal fourth quarter and year ended June 30, 2015, on Thursday, September 17, 2015.
Company’s Conference Call and Webcast
Management will host a conference call Thursday, September 17, 2015 at 2:00 PM Pacific (5:00 PM Eastern) to review the fiscal fourth quarter and year end financial results.
The call can be accessed by dialing 1-800-860-2442 within the U.S. or 1-412-858-4600 outside the U.S. and referencing, “Cesca.” Mr. Robin Stracey, Chief Executive Officer, Mr. Kenneth Harris, President and Mr. Michael Bruch, Interim Chief Financial Officer will be on the call to discuss the fourth quarter and year end results and other corporate events, followed by a Q&A session. Participants are asked to call the assigned number approximately five minutes before the conference call begins.
To listen to the audio webcast of the call during or after the event, please visit: http://cescatherapeutics.com/investors/webcasts-calls/.
Replay
A replay of the conference call will be available two hours after the call for the following five business days by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and entering the following account number when prompted 10071281.
About Cesca Therapeutics
Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
CONTACT: Cesca Therapeutics Inc. http://www.cescatherapeutics.com Investor Contact: Kirin Smith, ProActive Advisory Group + 1-646-863-6519, or ir@cescatherapeutics.com
Help employers find you! Check out all the jobs and post your resume.
